Rapamycin

Rapamycin is a prescription macrolide compound originally approved by the FDA for preventing organ rejection in transplant patients. In longevity circles it has attracted significant attention as the most reproducible pharmacological lifespan-extender ever tested in animals , but human evidence remains sparse, safety risks are real, and its use in healthy adults is entirely off-label.

What Is Rapamycin

Discovered in soil bacteria from Easter Island (Rapa Nui) in the 1970s, rapamycin was initially developed as an antifungal and later as an immunosuppressant. It is FDA-approved for renal transplant rejection, certain cancers, and rare lung diseases. Its use in healthy people seeking longevity benefits is not approved, not standard of care, and carries meaningful risks. Obtaining it requires a prescription; some longevity-focused clinicians will prescribe it off-label, but many will not.

mTOR Mechanism and Aging {#mtor-inhibition}

mTOR (mechanistic target of rapamycin) Complex 1 is a master nutrient-sensing kinase. When nutrients and growth signals are plentiful, mTORC1 is highly active , it drives cellular growth and protein synthesis while suppressing autophagy, the cellular recycling process that clears damaged proteins and organelles. Chronically elevated mTOR activity is associated with cellular senescence, reduced autophagy, and accelerated biological aging. Caloric restriction and fasting both suppress mTOR, and many researchers believe this is a key mechanism by which those interventions extend healthspan in animals.

Rapamycin inhibits mTORC1 directly, promoting autophagy, reducing the accumulation of senescent cells, and mimicking aspects of caloric restriction at the molecular level. At low doses, it primarily targets mTORC1; at higher doses it can also affect mTORC2, which has distinct and potentially harmful downstream effects including insulin resistance.

Animal Longevity Evidence

Rapamycin holds a unique distinction: it is the most robustly validated pharmacological lifespan-extender in mammals. In the Interventions Testing Program (ITP) , a rigorous multi-site NIA-funded program that has screened dozens of compounds , rapamycin consistently extends median lifespan by 10–25% in mice, even when treatment starts late in life (equivalent to mid-60s in humans). The effect has been replicated across laboratories, sexes, and genetic backgrounds, and similar results have been seen in flies, yeast, and worms. No other drug comes close to this level of cross-species replication in preclinical aging research.

Human Immune Evidence {#immune-function}

The most compelling human data does not come from longevity endpoints but from immune function. The TRITON trial and PEARL trial tested low-dose mTOR inhibitors (primarily everolimus, a rapamycin analogue) in older adults and found a roughly 20% improvement in response to influenza vaccination and a meaningful reduction in respiratory infection rates. These results are biologically coherent , mTOR inhibition at low doses appears to rejuvenate aspects of immune function that decline with age (immunosenescence) , and represent the best evidence that mTOR pathway modulation has tangible benefits in humans.

The Human Longevity Evidence Gap

Despite the compelling animal data and immune trial results, there is currently no randomized controlled trial demonstrating that rapamycin extends lifespan, slows biological aging, or reduces age-related disease burden in healthy adult humans. A 2024 Lancet Healthy Longevity systematic review found no such trials and concluded that clinical evidence is insufficient to support routine off-label use for longevity. Several trials are underway (PEARL extension, FAME trial, AgeMate trial), but results are years away. The translation from mouse models to humans is uncertain , mice are short-lived, inbred, and kept in controlled conditions; humans are long-lived, genetically diverse, and exposed to far more environmental variables.

Safety Concerns

Rapamycin is not a benign supplement. Documented adverse effects include:

• Elevated blood glucose and insulin resistance , mTORC2 inhibition at higher doses impairs insulin signaling; even at low doses, some users show transient glucose dysregulation
• Increased LDL cholesterol , reported in multiple contexts; cardiovascular risk implications unclear at longevity doses
• Infection susceptibility , as an immunosuppressant, rapamycin can impair immune defense; this risk is dose-dependent but not zero even at low doses
• Impaired wound healing , mTOR is important for tissue repair; rapamycin can slow healing after injury or surgery
• Mouth sores (stomatitis) , common at transplant doses; less common but possible at low doses

Bryan Johnson, one of the most public longevity self-experimenters, discontinued rapamycin after extended use, citing metabolic concerns. The risk-benefit calculation is genuinely unclear for healthy adults, and individual variation in response appears substantial.

Dosing in Longevity Protocols

Clinicians and researchers experimenting with off-label rapamycin in healthy adults typically use intermittent, low-dose protocols , most commonly 2–6 mg once weekly , rather than the daily dosing used in transplant medicine. The rationale is that intermittent dosing may preserve autophagy benefits while reducing the immunosuppressive and metabolic side effects of continuous exposure. However, this dosing approach has not been tested in RCTs; it is based on pharmacokinetic reasoning and anecdotal clinical observation.

Prescription-Only Warning

Rapamycin is a Schedule-free prescription drug in most jurisdictions but is not available over the counter. Using it without medical supervision is inadvisable. Anyone considering it should have full metabolic and immune baselines established, and should work with a physician who can monitor blood glucose, lipids, CBC, and immune markers during use. The compound is sometimes sold via compounding pharmacies or gray-market online sources , the quality and dosing accuracy of these products is unverified.